dc.creator | Bogavac-Stanojević, Nataša | |
dc.creator | Petrova, Guenka | |
dc.creator | Jelić-Ivanović, Zorana | |
dc.creator | Memon, Lidija | |
dc.creator | Spasić, Slavica | |
dc.date.accessioned | 2019-09-02T11:09:02Z | |
dc.date.available | 2019-09-02T11:09:02Z | |
dc.date.issued | 2007 | |
dc.identifier.issn | 0009-9120 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/903 | |
dc.description.abstract | Objectives: The aim of our study was to determine the cost-effectiveness of coronary artery disease (CAD) diagnostic parameters in a clinical laboratory setting. Design and methods: The effectiveness of apolipoproteins, lipoproteins and high sensitivity C-reactive protein (hs-CRP) supplementary to Framingham scoring data within a CAD risk assessment procedure was established in 221 CAD patients and 289 controls. The total costs of diagnostic procedures were calculated and incremental cost-effectiveness analysis was applied. Results: A diagnostic strategy employing Framingham calculation followed by apolipoprotein A-I (apoA-I) had the lowest cost per additional successfully diagnosed patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate-risk groups (2.96 vs. 122.85 euros). in the high-risk group the diagnostic strategy employing apoA-I saved 9.14 euros in comparison to the strategy employing hs-CRP. Conclusion: Cost-effectiveness analysis of different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society. | en |
dc.publisher | Pergamon-Elsevier Science Ltd, Oxford | |
dc.relation | info:eu-repo/grantAgreement/MESTD/MPN2006-2010/145036/RS// | |
dc.rights | restrictedAccess | |
dc.source | Clinical Biochemistry | |
dc.subject | cost-effectiveness | en |
dc.subject | coronary artery disease | en |
dc.subject | lipids | en |
dc.subject | lipoproteins | en |
dc.subject | Apolipoproteins | en |
dc.subject | hs-CRP | en |
dc.title | Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Спасић, Славица; Богавац-Станојевић, Наташа; Мемон, Лидија; Јелић-Ивановић, Зорана; Петрова, Гуенка; | |
dc.citation.volume | 40 | |
dc.citation.issue | 16-17 | |
dc.citation.spage | 1180 | |
dc.citation.epage | 1187 | |
dc.citation.other | 40(16-17): 1180-1187 | |
dc.citation.rank | M22 | |
dc.identifier.wos | 000250605200002 | |
dc.identifier.doi | 10.1016/j.clinbiochem.2007.07.004 | |
dc.identifier.pmid | 17869234 | |
dc.identifier.scopus | 2-s2.0-35248865222 | |
dc.type.version | publishedVersion | |